Olmetab Plus
Generic Name
Olmesartan Medoxomil + Hydrochlorothiazide
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmetab plus 20 mg tablet | ৳ 7.00 | ৳ 70.00 |
Description
Overview of the medicine
Olmetab Plus 20 mg Tablet is a combination medicine used to treat high blood pressure (hypertension). It contains Olmesartan Medoxomil, an angiotensin receptor blocker (ARB), and Hydrochlorothiazide, a thiazide diuretic.
Uses & Indications
Dosage
Adults
Typically one Olmetab Plus 20 mg/12.5 mg tablet once daily. Dose may be titrated by physician.
Elderly
No specific dose adjustment required, but caution is advised due to potential for reduced renal function.
Renal_impairment
Caution advised in patients with moderate to severe renal impairment. Not recommended in severe renal impairment (creatinine clearance <30 mL/min).
How to Take
Take orally, with or without food, preferably at the same time each day.
Mechanism of Action
Olmesartan blocks the action of angiotensin II, a substance in the body that constricts blood vessels, thus lowering blood pressure. Hydrochlorothiazide is a thiazide diuretic that increases the excretion of sodium and water from the body, leading to reduced blood volume and lower blood pressure.
Pharmacokinetics
Onset
Within 2 hours for blood pressure reduction; peak effect 1-2 weeks.
Excretion
Olmesartan: Biliary and renal excretion. Hydrochlorothiazide: Primarily renal excretion (unchanged).
Half life
Olmesartan: 10-15 hours. Hydrochlorothiazide: 5.6-14.8 hours.
Absorption
Olmesartan: Rapidly and completely absorbed, converted to active olmesartan. Hydrochlorothiazide: Rapidly absorbed.
Metabolism
Olmesartan: Little metabolism. Hydrochlorothiazide: Not metabolized significantly.
Side Effects
Contraindications
- •Hypersensitivity to olmesartan, hydrochlorothiazide, or sulfonamide-derived drugs.
- •Anuria.
- •Severe renal impairment (creatinine clearance <30 mL/min).
- •Severe hepatic impairment, biliary obstruction.
- •Pregnancy (especially second and third trimesters).
- •Concomitant use with aliskiren in patients with diabetes or renal impairment.
Drug Interactions
NSAIDs
Reduced antihypertensive effect and increased risk of renal impairment.
Lithium
Increased serum lithium concentrations and lithium toxicity.
Corticosteroids, ACTH
Increased risk of electrolyte depletion (especially hypokalemia with HCTZ).
Cholestyramine, Colestipol
May impair absorption of hydrochlorothiazide.
Potassium-sparing diuretics/Potassium supplements
Increased risk of hyperkalemia (with olmesartan).
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms include hypotension, tachycardia, bradycardia, electrolyte disturbances (e.g., hypokalemia). Management is supportive: IV fluids for hypotension, electrolyte correction, and monitoring.
Pregnancy & Lactation
Pregnancy: Category D (for olmesartan, especially 2nd and 3rd trimesters). Can cause fetal harm. Not recommended. Lactation: Both components excreted in breast milk. Not recommended during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
Approved by regulatory authorities (e.g., FDA, DGDA)
Patent Status
Generic versions available
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in